nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—FCGR activation—CD247—systemic scleroderma	0.107	0.242	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—CD247—systemic scleroderma	0.0633	0.144	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—CD247—systemic scleroderma	0.0327	0.0742	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—IRF5—systemic scleroderma	0.0294	0.0667	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—IRF8—systemic scleroderma	0.0281	0.0637	CbGpPWpGaD
Methyl aminolevulinate—Squamous cell carcinoma—Mycophenolic acid—systemic scleroderma	0.028	0.05	CcSEcCtD
Methyl aminolevulinate—Basal cell carcinoma—Mycophenolic acid—systemic scleroderma	0.027	0.0482	CcSEcCtD
Methyl aminolevulinate—Allergic contact dermatitis—Mometasone—systemic scleroderma	0.0263	0.0471	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Mometasone—systemic scleroderma	0.0258	0.0461	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—CD247—systemic scleroderma	0.0247	0.056	CbGpPWpGaD
Methyl aminolevulinate—Skin infection—Lisinopril—systemic scleroderma	0.0189	0.0339	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—HLA-DQB1—systemic scleroderma	0.0175	0.0398	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IRF5—systemic scleroderma	0.0144	0.0326	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IRF8—systemic scleroderma	0.0137	0.0311	CbGpPWpGaD
Methyl aminolevulinate—Stinging—Mometasone—systemic scleroderma	0.0114	0.0203	CcSEcCtD
Methyl aminolevulinate—Blister—Captopril—systemic scleroderma	0.0112	0.02	CcSEcCtD
Methyl aminolevulinate—Ulcer—Mometasone—systemic scleroderma	0.00972	0.0174	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.00959	0.0217	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.00916	0.0208	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis contact—Mometasone—systemic scleroderma	0.00909	0.0163	CcSEcCtD
Methyl aminolevulinate—Swelling—Pentoxifylline—systemic scleroderma	0.00877	0.0157	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—HLA-DQB1—systemic scleroderma	0.00856	0.0194	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Leflunomide—systemic scleroderma	0.00855	0.0153	CcSEcCtD
Methyl aminolevulinate—Ulcer—Captopril—systemic scleroderma	0.00854	0.0153	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Mycophenolic acid—systemic scleroderma	0.00816	0.0146	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Mycophenolic acid—systemic scleroderma	0.00796	0.0142	CcSEcCtD
Methyl aminolevulinate—Keratitis—Mycophenolate mofetil—systemic scleroderma	0.00773	0.0138	CcSEcCtD
Methyl aminolevulinate—Ulcer—Leflunomide—systemic scleroderma	0.00704	0.0126	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Leflunomide—systemic scleroderma	0.00658	0.0118	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Mycophenolate mofetil—systemic scleroderma	0.00644	0.0115	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Mycophenolate mofetil—systemic scleroderma	0.00628	0.0112	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Captopril—systemic scleroderma	0.00614	0.011	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.00572	0.013	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.00543	0.0123	CbGpPWpGaD
Methyl aminolevulinate—Eczema—Leflunomide—systemic scleroderma	0.00538	0.00962	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CSK—systemic scleroderma	0.00525	0.0119	CbGpPWpGaD
Methyl aminolevulinate—Swelling—Mycophenolic acid—systemic scleroderma	0.00523	0.00935	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD247—systemic scleroderma	0.00514	0.0117	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ITGAM—systemic scleroderma	0.00514	0.0117	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD247—systemic scleroderma	0.00493	0.0112	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Mycophenolic acid—systemic scleroderma	0.00482	0.00863	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TNFAIP3—systemic scleroderma	0.00481	0.0109	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Methotrexate—systemic scleroderma	0.00477	0.00854	CcSEcCtD
Methyl aminolevulinate—Erythema—Pentoxifylline—systemic scleroderma	0.00466	0.00833	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Captopril—systemic scleroderma	0.00463	0.00827	CcSEcCtD
Methyl aminolevulinate—Eczema—Lisinopril—systemic scleroderma	0.00462	0.00826	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—BLK—systemic scleroderma	0.00456	0.0104	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Mycophenolic acid—systemic scleroderma	0.00445	0.00796	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Methotrexate—systemic scleroderma	0.00409	0.00731	CcSEcCtD
Methyl aminolevulinate—Eye pain—Mycophenolate mofetil—systemic scleroderma	0.00403	0.00721	CcSEcCtD
Methyl aminolevulinate—Face oedema—Lisinopril—systemic scleroderma	0.00401	0.00717	CcSEcCtD
Methyl aminolevulinate—Discomfort—Pentoxifylline—systemic scleroderma	0.00392	0.00701	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Mycophenolate mofetil—systemic scleroderma	0.00381	0.00681	CcSEcCtD
Methyl aminolevulinate—Oedema—Pentoxifylline—systemic scleroderma	0.0038	0.0068	CcSEcCtD
Methyl aminolevulinate—Infection—Pentoxifylline—systemic scleroderma	0.00378	0.00676	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTLA4—systemic scleroderma	0.00374	0.00848	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Methotrexate—systemic scleroderma	0.00365	0.00652	CcSEcCtD
Methyl aminolevulinate—Ulcer—Prednisone—systemic scleroderma	0.00359	0.00642	CcSEcCtD
Methyl aminolevulinate—Face oedema—Mycophenolate mofetil—systemic scleroderma	0.00351	0.00628	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.00328	0.00586	CcSEcCtD
Methyl aminolevulinate—Infection—Mometasone—systemic scleroderma	0.00326	0.00583	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Prednisone—systemic scleroderma	0.00324	0.0058	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CSK—systemic scleroderma	0.00318	0.00722	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IRF5—systemic scleroderma	0.00313	0.0071	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Leflunomide—systemic scleroderma	0.00312	0.00559	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.00308	0.00698	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Pentoxifylline—systemic scleroderma	0.00302	0.0054	CcSEcCtD
Methyl aminolevulinate—Ulcer—Methotrexate—systemic scleroderma	0.003	0.00537	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IRF8—systemic scleroderma	0.00299	0.00679	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD247—systemic scleroderma	0.00299	0.00679	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ITGAM—systemic scleroderma	0.00299	0.00679	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Mycophenolic acid—systemic scleroderma	0.00298	0.00533	CcSEcCtD
Methyl aminolevulinate—Discomfort—Captopril—systemic scleroderma	0.00297	0.00531	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Mometasone—systemic scleroderma	0.00295	0.00527	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40LG—systemic scleroderma	0.00291	0.00659	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.00283	0.00642	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Mometasone—systemic scleroderma	0.00283	0.00506	CcSEcCtD
Methyl aminolevulinate—Pain—Mometasone—systemic scleroderma	0.00281	0.00502	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.0028	0.00501	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TNFAIP3—systemic scleroderma	0.0028	0.00636	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BLK—systemic scleroderma	0.00277	0.00628	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Pentoxifylline—systemic scleroderma	0.00273	0.00488	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Methotrexate—systemic scleroderma	0.00271	0.00485	CcSEcCtD
Methyl aminolevulinate—Pruritus—Pentoxifylline—systemic scleroderma	0.00269	0.00481	CcSEcCtD
Methyl aminolevulinate—Discomfort—Azathioprine—systemic scleroderma	0.00259	0.00464	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Captopril—systemic scleroderma	0.00259	0.00463	CcSEcCtD
Methyl aminolevulinate—Dizziness—Pentoxifylline—systemic scleroderma	0.00251	0.0045	CcSEcCtD
Methyl aminolevulinate—Erythema—Lisinopril—systemic scleroderma	0.0025	0.00447	CcSEcCtD
Methyl aminolevulinate—Infection—Azathioprine—systemic scleroderma	0.0025	0.00447	CcSEcCtD
Methyl aminolevulinate—Fatigue—Captopril—systemic scleroderma	0.00248	0.00444	CcSEcCtD
Methyl aminolevulinate—Discomfort—Leflunomide—systemic scleroderma	0.00245	0.00438	CcSEcCtD
Methyl aminolevulinate—Rash—Pentoxifylline—systemic scleroderma	0.0024	0.00429	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Pentoxifylline—systemic scleroderma	0.0024	0.00428	CcSEcCtD
Methyl aminolevulinate—Headache—Pentoxifylline—systemic scleroderma	0.00238	0.00426	CcSEcCtD
Methyl aminolevulinate—Face oedema—Prednisone—systemic scleroderma	0.00238	0.00426	CcSEcCtD
Methyl aminolevulinate—Infection—Leflunomide—systemic scleroderma	0.00236	0.00422	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mometasone—systemic scleroderma	0.00235	0.00421	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00235	0.00421	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mycophenolic acid—systemic scleroderma	0.00234	0.00418	CcSEcCtD
Methyl aminolevulinate—Pruritus—Mometasone—systemic scleroderma	0.00232	0.00415	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CTLA4—systemic scleroderma	0.00227	0.00514	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Mycophenolic acid—systemic scleroderma	0.00227	0.00405	CcSEcCtD
Methyl aminolevulinate—Nausea—Pentoxifylline—systemic scleroderma	0.00226	0.00404	CcSEcCtD
Methyl aminolevulinate—Infection—Mycophenolic acid—systemic scleroderma	0.00225	0.00403	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Leflunomide—systemic scleroderma	0.00213	0.00381	CcSEcCtD
Methyl aminolevulinate—Discomfort—Lisinopril—systemic scleroderma	0.0021	0.00376	CcSEcCtD
Methyl aminolevulinate—Rash—Mometasone—systemic scleroderma	0.00207	0.0037	CcSEcCtD
Methyl aminolevulinate—Asthenia—Captopril—systemic scleroderma	0.00207	0.0037	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mometasone—systemic scleroderma	0.00207	0.0037	CcSEcCtD
Methyl aminolevulinate—Headache—Mometasone—systemic scleroderma	0.00206	0.00368	CcSEcCtD
Methyl aminolevulinate—Fatigue—Leflunomide—systemic scleroderma	0.00205	0.00366	CcSEcCtD
Methyl aminolevulinate—Oedema—Lisinopril—systemic scleroderma	0.00204	0.00365	CcSEcCtD
Methyl aminolevulinate—Pruritus—Captopril—systemic scleroderma	0.00204	0.00365	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00203	0.00364	CcSEcCtD
Methyl aminolevulinate—Pain—Leflunomide—systemic scleroderma	0.00203	0.00363	CcSEcCtD
Methyl aminolevulinate—Infection—Lisinopril—systemic scleroderma	0.00203	0.00363	CcSEcCtD
Methyl aminolevulinate—Fatigue—Mycophenolic acid—systemic scleroderma	0.00195	0.00349	CcSEcCtD
Methyl aminolevulinate—Nausea—Mometasone—systemic scleroderma	0.00195	0.00349	CcSEcCtD
Methyl aminolevulinate—Pain—Mycophenolic acid—systemic scleroderma	0.00194	0.00347	CcSEcCtD
Methyl aminolevulinate—Dizziness—Captopril—systemic scleroderma	0.00191	0.00341	CcSEcCtD
Methyl aminolevulinate—Urticaria—Leflunomide—systemic scleroderma	0.00189	0.00337	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—HLA-DQB1—systemic scleroderma	0.00187	0.00424	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Azathioprine—systemic scleroderma	0.00185	0.00331	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00184	0.0033	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Lisinopril—systemic scleroderma	0.00183	0.00328	CcSEcCtD
Methyl aminolevulinate—Rash—Captopril—systemic scleroderma	0.00182	0.00325	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Captopril—systemic scleroderma	0.00182	0.00325	CcSEcCtD
Methyl aminolevulinate—Headache—Captopril—systemic scleroderma	0.00181	0.00323	CcSEcCtD
Methyl aminolevulinate—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00179	0.0032	CcSEcCtD
Methyl aminolevulinate—Infection—Mycophenolate mofetil—systemic scleroderma	0.00178	0.00318	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IL1A—systemic scleroderma	0.00177	0.00402	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD40LG—systemic scleroderma	0.00176	0.004	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Lisinopril—systemic scleroderma	0.00176	0.00315	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Leflunomide—systemic scleroderma	0.00175	0.00313	CcSEcCtD
Methyl aminolevulinate—Pain—Lisinopril—systemic scleroderma	0.00175	0.00312	CcSEcCtD
Methyl aminolevulinate—Nausea—Captopril—systemic scleroderma	0.00171	0.00306	CcSEcCtD
Methyl aminolevulinate—Asthenia—Leflunomide—systemic scleroderma	0.0017	0.00305	CcSEcCtD
Methyl aminolevulinate—Pruritus—Leflunomide—systemic scleroderma	0.00168	0.00301	CcSEcCtD
Methyl aminolevulinate—Dizziness—Azathioprine—systemic scleroderma	0.00166	0.00297	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.00163	0.00291	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mycophenolic acid—systemic scleroderma	0.00163	0.00291	CcSEcCtD
Methyl aminolevulinate—Urticaria—Lisinopril—systemic scleroderma	0.00162	0.0029	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00161	0.00287	CcSEcCtD
Methyl aminolevulinate—Pruritus—Mycophenolic acid—systemic scleroderma	0.0016	0.00287	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Prednisone—systemic scleroderma	0.00159	0.00285	CcSEcCtD
Methyl aminolevulinate—Rash—Azathioprine—systemic scleroderma	0.00159	0.00284	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Azathioprine—systemic scleroderma	0.00158	0.00283	CcSEcCtD
Methyl aminolevulinate—Headache—Azathioprine—systemic scleroderma	0.00158	0.00282	CcSEcCtD
Methyl aminolevulinate—Dizziness—Leflunomide—systemic scleroderma	0.00157	0.00281	CcSEcCtD
Methyl aminolevulinate—Pain—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00273	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Lisinopril—systemic scleroderma	0.0015	0.00269	CcSEcCtD
Methyl aminolevulinate—Dizziness—Mycophenolic acid—systemic scleroderma	0.0015	0.00268	CcSEcCtD
Methyl aminolevulinate—Rash—Leflunomide—systemic scleroderma	0.0015	0.00268	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Leflunomide—systemic scleroderma	0.0015	0.00268	CcSEcCtD
Methyl aminolevulinate—Nausea—Azathioprine—systemic scleroderma	0.00149	0.00267	CcSEcCtD
Methyl aminolevulinate—Headache—Leflunomide—systemic scleroderma	0.00149	0.00266	CcSEcCtD
Methyl aminolevulinate—Erythema—Prednisone—systemic scleroderma	0.00149	0.00266	CcSEcCtD
Methyl aminolevulinate—Asthenia—Lisinopril—systemic scleroderma	0.00146	0.00262	CcSEcCtD
Methyl aminolevulinate—Pruritus—Lisinopril—systemic scleroderma	0.00144	0.00258	CcSEcCtD
Methyl aminolevulinate—Rash—Mycophenolic acid—systemic scleroderma	0.00143	0.00256	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00143	0.00255	CcSEcCtD
Methyl aminolevulinate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00254	CcSEcCtD
Methyl aminolevulinate—Headache—Mycophenolic acid—systemic scleroderma	0.00142	0.00254	CcSEcCtD
Methyl aminolevulinate—Nausea—Leflunomide—systemic scleroderma	0.00141	0.00252	CcSEcCtD
Methyl aminolevulinate—Dizziness—Lisinopril—systemic scleroderma	0.00135	0.00241	CcSEcCtD
Methyl aminolevulinate—Nausea—Mycophenolic acid—systemic scleroderma	0.00135	0.00241	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Methotrexate—systemic scleroderma	0.00133	0.00238	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00236	CcSEcCtD
Methyl aminolevulinate—Rash—Lisinopril—systemic scleroderma	0.00129	0.0023	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Lisinopril—systemic scleroderma	0.00129	0.0023	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00229	CcSEcCtD
Methyl aminolevulinate—Headache—Lisinopril—systemic scleroderma	0.00128	0.00229	CcSEcCtD
Methyl aminolevulinate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00226	CcSEcCtD
Methyl aminolevulinate—Discomfort—Prednisone—systemic scleroderma	0.00125	0.00223	CcSEcCtD
Methyl aminolevulinate—Erythema—Methotrexate—systemic scleroderma	0.00124	0.00222	CcSEcCtD
Methyl aminolevulinate—Nausea—Lisinopril—systemic scleroderma	0.00121	0.00217	CcSEcCtD
Methyl aminolevulinate—Oedema—Prednisone—systemic scleroderma	0.00121	0.00217	CcSEcCtD
Methyl aminolevulinate—Infection—Prednisone—systemic scleroderma	0.0012	0.00215	CcSEcCtD
Methyl aminolevulinate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00211	CcSEcCtD
Methyl aminolevulinate—Rash—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00202	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00201	CcSEcCtD
Methyl aminolevulinate—Headache—Mycophenolate mofetil—systemic scleroderma	0.00112	0.002	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Prednisone—systemic scleroderma	0.00109	0.00195	CcSEcCtD
Methyl aminolevulinate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00106	0.0019	CcSEcCtD
Methyl aminolevulinate—Fatigue—Prednisone—systemic scleroderma	0.00105	0.00187	CcSEcCtD
Methyl aminolevulinate—Discomfort—Methotrexate—systemic scleroderma	0.00104	0.00187	CcSEcCtD
Methyl aminolevulinate—Infection—Methotrexate—systemic scleroderma	0.00101	0.0018	CcSEcCtD
Methyl aminolevulinate—Urticaria—Prednisone—systemic scleroderma	0.000963	0.00172	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IL1B—systemic scleroderma	0.000925	0.0021	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Methotrexate—systemic scleroderma	0.00091	0.00163	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Prednisone—systemic scleroderma	0.000893	0.0016	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methotrexate—systemic scleroderma	0.000873	0.00156	CcSEcCtD
Methyl aminolevulinate—Asthenia—Prednisone—systemic scleroderma	0.00087	0.00156	CcSEcCtD
Methyl aminolevulinate—Pain—Methotrexate—systemic scleroderma	0.000866	0.00155	CcSEcCtD
Methyl aminolevulinate—Pruritus—Prednisone—systemic scleroderma	0.000858	0.00153	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methotrexate—systemic scleroderma	0.000805	0.00144	CcSEcCtD
Methyl aminolevulinate—Dizziness—Prednisone—systemic scleroderma	0.000802	0.00143	CcSEcCtD
Methyl aminolevulinate—Rash—Prednisone—systemic scleroderma	0.000764	0.00137	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Prednisone—systemic scleroderma	0.000764	0.00137	CcSEcCtD
Methyl aminolevulinate—Headache—Prednisone—systemic scleroderma	0.000759	0.00136	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methotrexate—systemic scleroderma	0.000746	0.00133	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methotrexate—systemic scleroderma	0.000727	0.0013	CcSEcCtD
Methyl aminolevulinate—Nausea—Prednisone—systemic scleroderma	0.00072	0.00129	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methotrexate—systemic scleroderma	0.000717	0.00128	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methotrexate—systemic scleroderma	0.00067	0.0012	CcSEcCtD
Methyl aminolevulinate—Rash—Methotrexate—systemic scleroderma	0.000639	0.00114	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methotrexate—systemic scleroderma	0.000638	0.00114	CcSEcCtD
Methyl aminolevulinate—Headache—Methotrexate—systemic scleroderma	0.000635	0.00114	CcSEcCtD
Methyl aminolevulinate—Nausea—Methotrexate—systemic scleroderma	0.000602	0.00108	CcSEcCtD
